- Home
- ORKA vs OPK Comparison
ORKA vs OPK Comparison
Compare ORKA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- OPK
- Stock Information
- Founded
- ORKA 2004
- OPK 2007
- Country
- ORKA United States
- OPK United States
- Employees
- ORKA N/A
- OPK N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- OPK Health Care
- Exchange
- ORKA Nasdaq
- OPK Nasdaq
- Market Cap
- ORKA 354.2M
- OPK N/A
- IPO Year
- ORKA N/A
- OPK 1995
- Fundamental
- Price
- ORKA $12.60
- OPK $1.36
- Analyst Decision
- ORKA Strong Buy
- OPK Buy
- Analyst Count
- ORKA 8
- OPK 4
- Target Price
- ORKA $39.71
- OPK $2.75
- AVG Volume (30 Days)
- ORKA 341.3K
- OPK 3.5M
- Earning Date
- ORKA 08-15-2025
- OPK 08-06-2025
- Dividend Yield
- ORKA N/A
- OPK N/A
- EPS Growth
- ORKA N/A
- OPK N/A
- EPS
- ORKA N/A
- OPK N/A
- Revenue
- ORKA N/A
- OPK $689,408,000.00
- Revenue This Year
- ORKA N/A
- OPK N/A
- Revenue Next Year
- ORKA N/A
- OPK $7.80
- P/E Ratio
- ORKA N/A
- OPK N/A
- Revenue Growth
- ORKA N/A
- OPK N/A
- 52 Week Low
- ORKA $5.49
- OPK $1.19
- 52 Week High
- ORKA $52.32
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- OPK 56.84
- Support Level
- ORKA N/A
- OPK $1.26
- Resistance Level
- ORKA N/A
- OPK $1.36
- Average True Range (ATR)
- ORKA 0.00
- OPK 0.04
- MACD
- ORKA 0.00
- OPK 0.01
- Stochastic Oscillator
- ORKA 0.00
- OPK 92.31
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.